![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
复发性和耐火性扩散性大B细胞淋巴瘤的基因亚型引导免疫化学疗法:一个由研究者发起的第二阶段非随机临床试验 (GUIDANCE-06)
Yi-Ge Shen1, Qing Shi1, Wei Tang1
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Signal transduction and targeted therapy
|July 27, 2025
概括
这项研究表明,R-ICE-X是一种定制免疫化学疗法,对于复发性或耐火性扩散性大B细胞淋巴瘤 (R/R DLBCL) 是有效和安全的. 它通过针对特定的遗传和微环境因素,实现了高响应率和改善生存率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性或耐火性扩散性大B细胞淋巴瘤 (R/R DLBCL) 在治疗方面具有重大挑战,有效选择有限.
- 目前的治疗策略往往缺乏个性化,这导致许多患者的治疗结果不足.
研究的目的:
- 评估一种新的基因亚型引导免疫化疗方案 (R-ICE-X) 在R/R DLBCL患者的疗效和安全性.
- 评估R-ICE-X治疗的完整响应率 (CR),整体响应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
- 确定与治疗反应和疾病进展相关的预后因素和分子途径.
主要方法:
- 一个单中心的2期试验,涉及76名R/R DLBCL患者.
- 患者接受了针对特定遗传亚型 (例如,MCD类,BN2类,N1类,TP53Mut,EZB类,ST2类) 的R-ICE-X.
- 受访者进行了自身造血干细胞移植 (ASCT) 或R-ICE-X巩固和维护疗法.
主要成果:
- 该研究在诱导结束时实现了56.6%的完整响应率 (CR) 和76.3%的整体响应率 (ORR).
- 随访时间中位数为19.5个月,两年无进展生存率为69.3%,两年总生存率为88.3%.
- 常见的3-4级不良事件包括中性质衰竭 (30%) 和血小板衰竭 (25%). 大量的疾病和CD70突变是不良的预后指标.
结论:
- 在R/R DLBCL患者中,R-ICE-X显示出显著的疗效和可管理的安全性.
- 这种基于机制的,量身定制的疗法有效地针对基因和微环境的改变,改善结果.
- 中介细胞或炎症性淋巴瘤微环境亚型显示,R-ICE-X治疗特别有益.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K